Neuromuscular Diseases (Neuromuscular Disease)

Subscribe to Selected New Research on Neuromuscular Diseases

743 relevant articles (17 outcomes, 74 trials/studies) found for this Disease

Description: A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.

Also Known As:

Neuromuscular Disease; Amyotonia Congenita; Cramp-Fasciculation Syndrome; Fasciculation-Cramp Syndrome, Benign; Foley-Denny-Brown Syndrome; Oppenheim's Disease; Benign Fasciculation-Cramp Syndrome; Benign Fasciculation-Cramp Syndromes; Cramp Fasciculation Syndrome; Cramp-Fasciculation Syndromes; Fasciculation Cramp Syndrome, Benign; Fasciculation-Cramp Syndromes, Benign; Foley Denny Brown Syndrome; Oppenheims Disease; Syndrome, Cramp-Fasciculation; Syndrome, Foley-Denny-Brown; Syndromes, Cramp-Fasciculation; Oppenheim Disease

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3414

Neuromuscular Diseases: 743

Muscular Diseases: 4137

Peripheral Nervous System Diseases: 3231

Motor Neuron Disease: 841

Chronic Fatigue Syndrome: 573

Spinal Muscular Atrophy: 421

Stiff-Person Syndrome: 250

Atrophic Muscular Disorders: 149

Isaacs Syndrome: 130

Neuromuscular Junction Diseases: 20

Related Diseases

1.	Respiratory Insufficiency (Respiratory Failure)
2.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
3.	Congenital Abnormalities (Deformity)
4.	Syndrome
5.	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)

Experts

1.	Hendricks, Henk T: 2 articles (11/2007 - 05/2007)
2.	Pieterse, Allan J: 2 articles (11/2007 - 05/2007)
3.	Hill, Nicholas S: 2 articles (09/2006 - 06/2002)
4.	Dalakas, Marinos C: 2 articles (06/2004 - 05/2004)
5.	Miyashita, Mitsunori: 1 article (04/2008)
6.	Shirai, Yuki: 1 article (04/2008)
7.	Ichikawa, Yaeko: 1 article (04/2008)
8.	Abe, Yoshiki: 1 article (04/2008)
9.	Ito, Naomi: 1 article (04/2008)
10.	Momose, Yoshio: 1 article (04/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neuromuscular Diseases:

1.	Immunoglobulins (Immunoglobulin)IBA 08/15/1994 - "PATIENTS: 54 consecutive patients with various immune-related neuromuscular diseases participating in ongoing therapeutic trials of high-dose (2 g/kg) intravenous immunoglobulin" 10/01/1988 - "In the present study immunoglobulins from 4 of 8 ALS patients induced a significant increase in spontaneous quantal transmitter release as monitored by miniature end-plate potential (MEPP) frequency in mouse phrenic nerve-diaphragm preparations at 23 degrees C, whereas immunoglobulins from normal individuals and from patients with other neuromuscular diseases had no effect" 06/01/2004 - "The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile." 05/19/2004 - "Each autoimmune neuromuscular disease term was searched in combination with the term intravenous immunoglobulin" 05/19/2004 - "Intravenous immunoglobulin in autoimmune neuromuscular diseases." Order ALL the reference details at left...
2.	CreatineIBA 01/01/2002 - "This is because of the widespread use of creatine by athletes, on the one hand, and to some promising results regarding its therapeutic potential in neuromuscular disease on the other" 01/01/2007 - "SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group Register in May 2004 for randomised trials using the search term 'creatine'" 01/01/2004 - "The pharmacokinetics and rationale for the use of creatine are described along with available evidence from animal models and clinical trials for ALS and related neurodegenerative or neuromuscular diseases." 03/10/1999 - "Creatine monohydrate (10 g daily for 5 days to 5 g daily for 5 days) was administered to patients with neuromuscular disease in a pilot study (Study 1; n = 81), followed by a single-blinded study (Study 2; n = 21)" 01/01/2007 - "Little is known about creatine disposition in special populations including the elderly and patients with neuromuscular disease" Order ALL the reference details at left...
3.	Intravenous Immunoglobulins (IVIG)FDA Link 05/19/2004 - "OBJECTIVE: To systematically review the current status of the treatment of autoimmune neuromuscular diseases with IVIG, with emphasis on controlled trials" 01/01/1993 - "We will present current experience with IVIG in the above-mentioned autoimmune neuromuscular diseases, and we will stress the need for long-term controlled studies" 01/01/1998 - "This phenomenon may be important in interpreting the (side) effects of IVIg in neuromuscular diseases." 02/01/1997 - "Treatment of autoimmune neuromuscular diseases with intravenous immunoglobulins]" 01/01/1993 - "Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin." Order ALL the reference details at left...
4.	DystrophinIBA 08/01/2000 - "In cases from whom frozen muscle sections cannot be obtained, immunohistochemical dystrophin analysis using the Catalyzed Signal Amplification system will be beneficial for the diagnosis and the screening of neuromuscular diseases." 01/01/2005 - "In this study, therefore, we examined how two neuromuscular diseases, dystrophin-deficiency and laminin-alpha2-deficiency, altered the proliferation and composition of different subsets of muscle-derived mononucleate cells" 03/01/2002 - "We studied the expression of dystrophin in skin biopsy samples from 19 patients with neuromuscular diseases" 11/01/1996 - "Dystrophin immunostaining confirmed absent reaction in the arrector pili muscles of DMD patients, faint positive reaction in BMD patients, and strong dystrophin reaction in patients with other neuromuscular diseases and normal controls" 05/01/1994 - "Immunohistochemical method detecting dystrophin in muscle biopsies was introduced and applied in 121 cases with a large scale of neuromuscular diseases" Order ALL the reference details at left...
5.	AntibodiesIBA 06/01/1991 - "Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera." 12/01/2004 - "Neuromuscular diseases associated with antigliadin antibodies" 12/01/1997 - "Estimation of circulating antigliadin antibodies should be considered in all patients with neuromuscular disease of otherwise obscure aetiology." 02/01/1997 - "The finding also supports a possible pathogenic role for the previously reported, high titer, high affinity, inhibitory AChE antibodies in the neuromuscular disease." 01/01/1986 - "Circulating antibodies and their diagnostic value in neuromuscular diseases]" Order ALL the reference details at left...
6.	GangliosidesIBA 01/01/1995 - "Compared with DMD cases and non-neuromuscular disease controls, FCMD cases showed a reduction of total gangliosides, and an abnormal, immature ganglioside pattern in the cerebral gray and white matter" 04/01/1994 - "Despite these findings there is still little evidence that treatment with parenteral gangliosides in humans can be effective in peripheral neuropathies or other neuromuscular diseases" 11/01/1988 - "We report three 12-month, double-blind, three-phase studies comparing the effect of placebo and 40 mg and 100 mg IM daily of purified bovine brain gangliosides (Cronassial) in chronic neuromuscular diseases" 10/01/1995 - "The expression of neutral glycosphingolipids (GSLs) and gangliosides was investigated in cryosections of normal mouse skeletal muscle and in muscle of mice with neuromuscular diseases using indirect immunofluorescence microscopy" 10/01/1995 - "Immunohistological analyses of neutral glycosphingolipids and gangliosides in normal mouse skeletal muscle and in mice with neuromuscular diseases." Order ALL the reference details at left...
7.	Carbon MonoxideIBA 02/01/2000 - "CONCLUSIONS: The present study shows that in patients with neuromuscular disease, elastic load and respiratory muscle weakness are responsible for a rapid and shallow breathing pattern leading to chronic CO(2) retention." 07/01/2000 - "Since the identification of Neospora caninum in 1984 as a parasite separate from Toxoplasma gondii by Bjerkas et al., and its subsequent characterization and classification in 1988 by Dubey and co-workers, this parasite has attracted increasing attention, primarily as an important causative agent of abortion in cattle and neuromuscular disease in dogs, but also as a complementary model system to T" 02/01/2000 - "Mechanism of CO(2) retention in patients with neuromuscular disease." 12/01/2006 - "The use of short-acting anaesthetics, drugs to reduce blood loss, experienced spinal anaesthetists and the availability of intensive care support are all essential for a good outcome in patients with neuromuscular disease and cardiopulmonary co-morbidity." 02/16/2008 - "The complex is formed of HspB8, a member of the HspB family of molecular chaperones, which is found mutated in neuromuscular diseases, and Bag3, a member of the co-chaperone family of Bag domain-containing proteins" Order ALL the reference details at left...
8.	GasesIBA 01/01/1999 - "Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases." 05/01/1999 - "Twenty-seven patients with chest wall deformity or neuromuscular disease underwent analysis of overnight oximetry, blood gases, and 24 h heart rate variability (HRV), specifically the standard deviation of normal-to-normal (SDNN) RR intervals, and the number of increases in successive NN intervals >50 ms (SNN50)" 04/11/1990 - "Nocturnal ventilation in respiratory insufficiency due to neuromuscular disease and/or thoracic deformity leads to improvement in the quality of life and daytime arterial blood gases, and also in survival" 03/01/1980 - "Hyperventilation gases must be interpreted with care in neuromuscular disease; the ability to reduce PCO2 to normal range does not exclude neuromuscular disease as a cause of chronic respiratory failure." 07/01/1987 - "Persons with alveolar hypoventilation have abnormal daytime arterial blood gases and abnormal responses to hypercapnia and hypoxia in the absence of any identifiable lung or neuromuscular disease" Order ALL the reference details at left...
9.	Botulinum Toxins (Botulinum Toxin)IBA 12/01/2000 - "It may also be useful in motor point biopsy for diagnosis of neuromuscular diseases as well as in the botulinum toxin injection for the treatment of spasticity." 10/01/1999 - "Botulinum toxin A has been used to treat a spectrum of neuromuscular diseases" 02/01/1997 - "To evaluate its efficacy in treating muscle cramping syndromes, we studied clinical and neurophysiological variables before and after botulinum toxin injections into calf muscles and small flexor muscles of the foot in patients with an inherited benign cramp-fasciculation syndrome" Order ALL the reference details at left...
10.	Apolipoprotein E2IBA 11/01/2000 - "Third, the APOE2 allele seems to confer protection against developing certain neuromuscular diseases, including the amyotrophic lateral sclerosis (ALS)/parkinsonism/dementia complex of Guam" Order ALL the reference details at left...

Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation) 08/01/2008 - "We postulated that for parents living with the constant demands of caring for their child with neuromuscular disease requiring home mechanical ventilation, these caretaking demands, over time, had become part of "normal" life and were not identified as creating additional stress." 08/01/2008 - "One hundred and nine families participated; 19 (17%) families had a child with neuromuscular disease requiring home mechanical ventilation" 08/01/2008 - "Adults requiring at least 5 days of mechanical ventilation without evidence of preexisting neuromuscular disease were followed until awakening and were then examined for strength" 03/01/2008 - "Non-invasive (NIV) as well as invasive mechanical ventilation are established for the treatment of ventilatory failure in neuromuscular diseases" 09/01/2007 - "BACKGROUND AND OBJECTIVES: Current international consensus guidelines identify a number of indicators for the establishment of home mechanical ventilation (HMV) for patients with neuromuscular diseases but do not address the possible clinical differences between each of the underlying disorders" Order ALL the reference details at left...
2.	Positive-Pressure Respiration (PEEP) 11/01/2006 - "Non-invasive positive pressure ventilation for neuromuscular diseases" 11/01/2006 - "Searching the literature for non-invasive positive pressure ventilation for neuromuscular diseases]" 11/01/2006 - "Non-invasive positive pressure ventilation for neuromuscular diseases" 01/01/2006 - "The use of noninvasive positive pressure ventilation (NPPV) is increasingly accepted as a treatment of respiratory problems in patients with neuromuscular disease" 02/01/2004 - "Outcome of non-invasive positive pressure ventilation in paediatric neuromuscular disease." Order ALL the reference details at left...
3.	Critical Care 09/01/2006 - "Neuromuscular disease in respiratory and critical care medicine." 11/01/2004 - "This is of particular interest in the investigation of patients receiving critical care, those with neuromuscular disease, and in children where volitional efforts are either not possible or likely to be sub-maximal" 04/01/2003 - "Critical care management of neuromuscular disease, including long-term ventilation." 12/01/2002 - "SETTING: Neuro-critical care unit of a tertiary care center in an urban area with a large, established, regional neuromuscular disease program" 04/01/2003 - "PURPOSE OF REVIEW: This review highlights recent advances in the critical care management of neuromuscular disease, particularly in the long-term management of chronic respiratory failure occurring as a consequence of neuromuscular disease" Order ALL the reference details at left...
4.	Arthroplasty 01/01/2000 - "Total hip arthroplasty in patients with neuromuscular disease." 10/01/1999 - "MATERIALS AND METHODS: We reviewed retrospectively 14 consecutive patients with neuromuscular disease, who had 18 total arthroplasties of paralytic hips" 03/01/1986 - "Controversy exists over the appropriate use of total hip arthroplasty in patients with significant neuromuscular disease" 03/01/1986 - "Conclusion: Total hip arthroplasty is a reasonable and safe therapeutic option for the treatment of painful osteoarthritis of the hip in select patients with neuromuscular disease." 06/01/2006 - "Indications for constraint include recurrent hip instability after arthroplasty, intraoperative multidirectional hip instability, neuromuscular diseases that impair hip dynamics, neurologic diseases that impair the patient's ability to restrict activities, and proximal muscle weakness with or without deficiency of the protective muscular" Order ALL the reference details at left...
5.	Intensive Care (Surgical Intensive Care) 02/01/2004 - "AIMS: To determine the outcome of children with neuromuscular disease (NMD) following admission to a tertiary referral paediatric intensive care (PICU)" 02/01/2004 - "Outcome of children with neuromuscular disease admitted to paediatric intensive care." 11/01/2004 - "In particular, the use of magnetic stimulation in neuromuscular disease, the intensive care setting, chronic obstructive pulmonary disease and paediatrics will be discussed." 12/01/2006 - "The use of short-acting anaesthetics, drugs to reduce blood loss, experienced spinal anaesthetists and the availability of intensive care support are all essential for a good outcome in patients with neuromuscular disease and cardiopulmonary co-morbidity." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Neuromuscular Diseases

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 17 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>